Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001

Life Sciences

Volumn 88, Issue 9-10, 2011, Pages 418-424

  Wedel, Steffen ^a   Hudak, Lukasz ^a   Seibel, Jens Michael ^a   Juengel, Eva ^a   Tsaur, Igor ^a   Wiesner, Christoph ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cell cycle; Cyclins; HDAC; mTOR; Prostate carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; S6 KINASE; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PROSTATE CANCER; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; VALPROIC ACID;

MAMMALIA;

EID: 79951952760     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.12.017     Document Type: Article

References (31)

1. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival. Prostate 1999;38(3):175-82. (Pubitemid 29054933)
2. Blaheta RA, Michaelis M, Driever PH, Cinatl Jr J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25(4):383-97. (Pubitemid 40946533)
3. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66(20):10040-7. (Pubitemid 44672057)
4. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 2006;103(43):15969-74. (Pubitemid 44657576)
5. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer 2007;96(6):970-9. (Pubitemid 46452276)
6. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2009 [Epub ahead of print].
7. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson III AB, Burstein HJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Cancer Netw 2008;6(Suppl 5):S1-S20.
8. George DJ, Armstrong AJ, Creel P, Morris K, Madden J, Turnbull J. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer. Genitourinary Cancers Symposium, Abstract 181; 2008.
9. Graff JR. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 2002;6(1):103-13. (Pubitemid 46804571)
10. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, et al. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 1999;38(1):40-5.
11. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59(2):177-89. (Pubitemid 38481229)
12. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2009;13(8B):2376-85.
13. Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, et al. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate 2010;70(8):866-74.
14. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006;66(11):1203-12. (Pubitemid 44175342)
15. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008;7(12):1745-62. (Pubitemid 351988740)
16. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 2008;27(34):4733-44.
17. Maddison LA, Huss WJ, Barrios RM, Greenberg NM. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate 2004;58(4):335-44.
18. Mahalingam D, Medina EC, Esquivel 2nd JA, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010;16(1):141-53.
19. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR. Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003;161(4):817-26.
20. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59(17):4291-6. (Pubitemid 29418745)
21. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18(4):769-74.
22. Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, et al. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol 2009;174(5):1921-30.
23. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008;7(12):1828-35. (Pubitemid 351988749)
24. Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y, et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 2007;100(3):685-90. (Pubitemid 47205471)
25. Son DJ, Park MH, Chae SJ, Moon SO, Lee JW, Song HS, et al. Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB. Mol Cancer Ther 2007;6(2):675-83. (Pubitemid 46332468)
26. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008;14(11):3589-97.
27. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008;33(2):375-80.
28. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 2010;109(4):726-36.
29. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98(3):604-10. (Pubitemid 351214528)
30. Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66(14):7237-44. (Pubitemid 44197704)
31. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009;69(18):7466-72.